ProCE Banner Series

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy

Register now for this CME/ABIM MOC-certified interactive workshop series on therapeutic advances and novel approaches to targeted therapy in relapsed/refractory DLBCL!

  AMA
Who Should Attend

The intended audience for this educational initiative includes community hematologists, oncologists, and other clinicians involved in the care of patients with DLBCL.

All Events

Past Events

June

29

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy

5:15 PM - 6:15 PM Central Time (CT)

Virtual

July

08

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy

12:05 PM - 1:05 PM Eastern Time (ET)

In-person

July

11

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy

4:30 PM - 5:30 PM Central Time (CT)

Virtual

Private Event | Virtual Group, Norman, Oklahoma

August

02

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy

7:00 PM - 8:00 PM Eastern Time (ET)

In-person

Private Event | Host Group at Sevan, Oakland Gardens, New York

August

15

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy [Open Registration]

3:30 PM - 4:30 PM Mountain Time (MT)

Virtual

CCO Simulcast | Host Group NM, Rio Rancho, New Mexico

September

23

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy

2:00 PM - 3:00 PM Mountain Time (MT)

In-person

Private Event | Host Group at Hyatt, Park City, Utah

September

26

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Private Event | Virtual Group MI, Royal Oak, Michigan

September

29

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy

4:00 PM - 5:00 PM Eastern Time (ET)

In-person

Private Event | Quality Cancer Care Alliance Fall Educational and Leadership Summit, Boston, Massachusetts

September

29

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy

5:00 PM - 6:00 PM Eastern Time (ET)

In-person

Private Event | Quality Cancer Care Alliance Fall Educational and Leadership Summit, Boston, Massachusetts

October

12

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy

12:00 PM - 1:00 PM Central Time (CT)

Virtual

Private Event | Virtual Group AL, Birmingham, Alabama

October

18

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy

11:30 AM - 12:30 PM Central Time (CT)

Virtual

Simulcast | Host Group TX, San Antonio, Texas

October

31

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy [Open Registration]

11:00 AM - 12:00 PM Mountain Time (MT)

Virtual

Private Event | Virtual Group CO, Colorado Springs, Colorado

November

02

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy

4:30 PM - 5:30 PM Eastern Time (ET)

Virtual

Private Event | Virtual Group, Brooklyn, New York

November

08

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy [Open Registration]

8:00 AM - 9:00 AM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group NJ, Elizabeth, New Jersey

November

13

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy [Open Registration]

11:30 AM - 12:30 PM Central Time (CT)

Virtual

CCO Simulcast | Host Group TX, Dallas, Texas

November

29

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy [Open Registration]

7:30 AM - 8:30 AM Central Time (CT)

Virtual

CCO Simulcast | Host Group NE, Lincoln, Nebraska

December

01

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy [Open Registration]

7:00 AM - 8:00 AM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group NC, Hendersonville, North Carolina

December

05

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy

7:30 AM - 8:30 PM Eastern Time (ET)

Virtual

Private Event, Bennington, Vermont

December

15

2023

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy

9:00 AM - 10:00 AM Pacific Time (PT)

Virtual

Virtual Event | Host Group in ID, Post Falls, Idaho

January

05

2024

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy

11:00 AM - 12:00 PM Central Time (CT)

Virtual

Private Event | Virtual Group, Vicksburg, Mississippi

Faculty

ProCE Banner Faculty
John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

ProCE Banner Faculty
John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

ProCE Banner Faculty
Erin Dean, MD

Assistant Professor
Department of Medicine, Division of Hematology and Oncology
University of Florida
Gainesville, Florida

ProCE Banner Faculty
Ian W. Flinn, MD, PhD

Director
Lymphoma Research Program
Sarah Cannon Research Institute
Program Director
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee

ProCE Banner Faculty
Caron Jacobson, MD

Associate Professor of Medicine
Harvard Medical School
Medical Director, Immune Effector Cell Therapy Program
Dana-Farber Cancer Institute
Boston, Massachusetts

ProCE Banner Faculty
Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

ProCE Banner Faculty
Priyanka Pophali, MD

Assistant Professor
Division of Hematology, Medical Oncology, and Palliative Care
Department of Medicine
University of Wisconsin, Carbone Cancer Center
UW Health
Madison, Wisconsin

Topics

Welcome and Introductions
Advances in the Treatment of R/R DLBCL
•    NCCN clinical treatment guidelines
•    Data supporting recently approved targeted therapy options
•    Expert recommendations on selecting between treatment options
Emerging Options for Personalized Patient Care
•    Potential therapeutic targets and new treatment modalities for DLBCL
•    Targeted therapies in late-stage development
•    Potential role of new therapies in the treatment paradigm
•    Important of clinical trial enrollment
Audience Q&A

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners in selecting individualized treatments for patients with relapsed or refractory diffuse large B-cell lymphomas.

Target Audience
The intended audience for this educational initiative includes community hematologists, oncologists, and other clinicians involved in the care of patients with DLBCL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Outline the most recent treatment guidelines for relapsed/refractory DLBCL, including the role of novel targeted therapies in the treatment paradigm
  • Evaluate novel targeted therapies currently in development for treatment of relapsed/refractory DLBCL
  • Develop personalized treatment plans for patients with relapsed/refractory DLBCL based on clinical trial data and guideline and expert recommendations

 

Accreditation

Relevant Financial Relationships Disclosures:

USF Health and Rockpointe adhere to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. Prior to the activity, USF Health will disclose and mitigate all relevant financial relationships that relate to the content of the activity.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and Rockpointe. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about accreditation of this activity, please email: cpdsupport@usf.edu 

ABIM MOC RECOGNITION STATEMENT


Successful completion of the CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is USF Health’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through USF Health’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Participants will earn MOC Points equivalent to the amount of CME credits claimed for the activity. USF Health will submit within 60 days the Participant’s MOC Points. No MOC certificates will be provided. Participants with questions regarding their Points, should contact USF Health at cpdsupport@usf.edu.

Acknowledgement

Jointly provided by USF Health and Rockpointe.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.